The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04880031
Recruitment Status : Active, not recruiting
First Posted : May 10, 2021
Last Update Posted : May 21, 2024
Sponsor:
Information provided by (Responsible Party):
Boston Pharmaceuticals

Brief Summary:
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis (NASH) Drug: BOS-580 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
Actual Study Start Date : September 30, 2021
Estimated Primary Completion Date : December 15, 2024
Estimated Study Completion Date : December 15, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Experimental: Cohort A1: BOS-580 Dose 1 or placebo (PBO) Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection

Experimental: Cohort A2: BOS-580 Dose 2 or PBO Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection

Experimental: Cohort A3: BOS-580 Dose 3 or PBO Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection

Experimental: Cohort A4: BOS-580 Dose 4 or PBO Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection

Experimental: Cohort A5: BOS-580 Dose 5 or PBO Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection

Experimental: Cohort B: BOS-580 Dose 1 or PBO Drug: BOS-580
BOS-580 will be administered by subcutaneous injection

Drug: Placebo
Placebo will be administered by subcutaneous injection




Primary Outcome Measures :
  1. Part A and Part B: Number of participants with treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE) [ Time Frame: Until End of study/Early Termination (Day 197) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  2. Part A and Part B: Changes from Baseline to Week 12 (Day 85) in systolic and diastolic blood pressure (BP) [ Time Frame: Baseline, Week 12 (Day 85) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  3. Part A and Part B: Changes from Baseline to Week 12 (Day 85) in heart rate [ Time Frame: Baseline, Week 12 (Day 85) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  4. Part A and Part B: Number of participants with Grade 3 and Grade 4 laboratory abnormalities at Week 12 (Day 85) [ Time Frame: Week 12 (Day 85) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  5. Part B only: Changes from Baseline to Week 24 (Day 169) and Week 28 (Day 197) in systolic and diastolic BP [ Time Frame: Baseline, Week 24 (Day 169), Week 28 (Day 197) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  6. Part B only: Changes from Baseline to Week 24 (Day 169) and Week 28 (Day 197) in heart rate [ Time Frame: Baseline, Week 24 (Day 169), Week 28 (Day 197) ]
    The effects of BOS-580 on safety and tolerability will be assessed.

  7. Part B only: Number of participants with Grade 3 and Grade 4 laboratory abnormalities at Week 24 (Day 169) and Week 28 (Day 197) [ Time Frame: Week 24 (Day 169) and Week 28 (Day 197) ]
    The effects of BOS-580 on safety and tolerability will be assessed.


Secondary Outcome Measures :
  1. Part A only: BOS-580 serum concentration on Day 8 of the first dose [ Time Frame: Day 8 ]
    The pharmacokinetics (PK) of BOS-580 will be assessed.

  2. Part A only: BOS-580 serum concentration at the end of the dosing interval (Ctrough) [ Time Frame: Pre-dose at Days 15, 29, 43, 57, 71, 85 and 113 (End of study/Early termination) for bi-weekly schedule; pre-dose on Days 29, 57, 85 and 113 (End of study/Early termination) for the monthly schedule ]
    The pharmacokinetics (PK) of BOS-580 will be assessed.

  3. Part B only: BOS-580 serum concentration on Day 7 [ Time Frame: Day 7 ]
    The PK of BOS-580 will be assessed.

  4. Part B only: BOS-580 serum concentration at the end of the dosing interval (Ctrough) [ Time Frame: Pre-dose at Days 29, 57, 85, 113, 141, 169 and at Day 196 (End of study/Early Termination) ]
    The PK of BOS-580 will be assessed.

  5. Part B Only: Area under the serum concentration-time curve (AUC) for BOS-580 for one dosing interval at steady state [ Time Frame: At Days 121, 127, 134 and pre-dose at Day 141 ]
    The PK of BOS-580 will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the informed consent
  • Obese participants with body mass index (BMI) of ≥ 27 kg/m^2
  • Hepatic fat fraction (HFF) measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) ≥8%
  • Liver fibrosis assessment based on a vibration controlled transient elastography (VCTE) liver stiffness measurement (LSM) score of 7.0 to 9.9 kPa (Part A only) inclusive or 7.0 to 20.0 kPa (Part B only) inclusive and Liver injury assessment measured by aspartate aminotransferase (AST) >25U/L. A qualifying historical biopsy (confirmed eligibility based on the central pathology read) supersedes the LSM, controlled attenuation parameter (CAP) score criteria and AST criteria.
  • Histopathologically confirmed F2 or F3 stage NASH on a diagnostic liver biopsy performed during Screening or within 6 months prior to the first day of dosing for historical biopsies (Part B only).
  • History or presence of at least 2 of 4 components of metabolic syndrome: obesity/overweight, dyslipidemia (high triglycerides and/or low high density lipoprotein [HDL]), type 2 diabetes with elevated glycated hemoglobin (HbA1c), and hypertension.

Exclusion Criteria:

  • Documented clinical, laboratory or radiologic evidence of cirrhosis (compensated or decompensated)
  • Triglycerides ≥ 500 mg/dL
  • Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months from Screening, whichever is smaller)
  • History of type 1 diabetes, diabetic ketoacidosis, or positive glutamic acid decarboxylase (GAD) auto-antibodies (latent autoimmune diabetes in adults)
  • Hemoglobin A1c > 9.5%
  • Subjects with a condition that requires substantial anticoagulant medication may not be eligible for the study enrollment (e.g., deep vein thrombosis).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04880031


Locations
Show Show 39 study locations
Sponsors and Collaborators
Boston Pharmaceuticals
Layout table for additonal information
Responsible Party: Boston Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04880031    
Other Study ID Numbers: BOS-580-201
First Posted: May 10, 2021    Key Record Dates
Last Update Posted: May 21, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Boston Pharmaceuticals:
BOS-580
Safety
Tolerability
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases